These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28604280)

  • 1. The anticoagulant effects of warfarin and the bleeding risk associated with its use in patients with chronic thromboembolic pulmonary hypertension at a specialist center in Japan: a retrospective cohort study.
    Jujo-Sanada T; Tanabe N; Sakao S; Sugiura T; Sekine A; Nishimura R; Suda R; Naito A; Miwa H; Yamamoto K; Sasaki A; Matsumura A; Ema R; Kasai H; Kato F; Tatsumi K
    Pulm Circ; 2017; 7(3):684-691. PubMed ID: 28604280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life data of direct anticoagulant use, bleeding risk and venous thromboembolism recurrence in chronic thromboembolic pulmonary hypertension patients: an observational retrospective study.
    Sena S; Bulent M; Derya K; Deniz K; Halil A; Okan E; Bedrettin Y
    Pulm Circ; 2020; 10(1):2045894019873545. PubMed ID: 32128155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension.
    Bunclark K; Newnham M; Chiu YD; Ruggiero A; Villar SS; Cannon JE; Coghlan G; Corris PA; Howard L; Jenkins D; Johnson M; Kiely DG; Ng C; Screaton N; Sheares K; Taboada D; Tsui S; Wort SJ; Pepke-Zaba J; Toshner M
    J Thromb Haemost; 2020 Jan; 18(1):114-122. PubMed ID: 31557382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Anticoagulation Outcomes and Venous Thromboembolism History in Chronic Thromboembolic Pulmonary Hypertension.
    Zhu YJ; Zhou YP; Wei YP; Xu XQ; Yan XX; Liu C; Zhu XJ; Liu ZY; Sun K; Hua L; Jiang X; Jing ZC
    Front Cardiovasc Med; 2021; 8():628284. PubMed ID: 34095244
    [No Abstract]   [Full Text] [Related]  

  • 5. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting.
    Willey VJ; Bullano MF; Hauch O; Reynolds M; Wygant G; Hoffman L; Mayzell G; Spyropoulos AC
    Clin Ther; 2004 Jul; 26(7):1149-59. PubMed ID: 15336480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of chronic thromboembolic pulmonary hypertension using direct oral anticoagulants and warfarin: a Japanese prospective cohort study.
    Hosokawa K; Abe K; Funakoshi K; Tamura Y; Nakashima N; Todaka K; Taniguchi Y; Inami T; Adachi S; Tsujino I; Yamashita J; Minatsuki S; Ikeda N; Shimokawahara H; Kawakami T; Ogo T; Hatano M; Ogino H; Fukumoto Y; Tanabe N; Matsubara H; Fukuda K; Tatsumi K; Tsutsui H
    J Thromb Haemost; 2023 Aug; 21(8):2151-2162. PubMed ID: 37044277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
    Raskob G; Ageno W; Cohen AT; Brekelmans MP; Grosso MA; Segers A; Meyer G; Verhamme P; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
    Lancet Haematol; 2016 May; 3(5):e228-36. PubMed ID: 27132697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleeding, Recurrent Venous Thromboembolism, and Mortality Risks During Warfarin Interruption for Invasive Procedures.
    Clark NP; Witt DM; Davies LE; Saito EM; McCool KH; Douketis JD; Metz KR; Delate T
    JAMA Intern Med; 2015 Jul; 175(7):1163-8. PubMed ID: 26010033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
    Wu C; Alotaibi GS; Alsaleh K; Linkins LA; McMurtry MS
    Thromb Res; 2015 Feb; 135(2):243-8. PubMed ID: 25488466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
    Marik PE; Cavallazzi R
    PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events.
    Chen SY; Wu N; Gulseth M; LaMori J; Bookhart BK; Boulanger L; Fields L; Schein J
    J Manag Care Pharm; 2013 May; 19(4):291-301. PubMed ID: 23627575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital.
    Cieri NE; Kusmierski K; Lackie C; Van Opdorp A; Hassan AK
    Pharmacotherapy; 2017 Feb; 37(2):170-176. PubMed ID: 28028830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and risk factors of chronic thromboembolic pulmonary hypertension following venous thromboembolism, a population-based cohort study in England.
    Martinez C; Wallenhorst C; Teal S; Cohen AT; Peacock AJ
    Pulm Circ; 2018; 8(3):2045894018791358. PubMed ID: 29985100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Warfarin Failure in a Patient With Chronic Thromboembolic Pulmonary Hypertension: A Case Report and Literature Review.
    Dolkar T; Chaudry A; Salauddin F; Nway N; Kadakia N; Kalavar M; Dogar MH
    Cureus; 2022 Jul; 14(7):e27007. PubMed ID: 35989750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study.
    Roberts MZ; Gaskill GE; Kanter-Washko J; Kyle TR; Jones BC; Bohm NM
    J Thromb Thrombolysis; 2018 May; 45(4):512-515. PubMed ID: 29556958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice.
    Weycker D; Li X; Wygant GD; Lee T; Hamilton M; Luo X; Vo L; Mardekian J; Pan X; Burns L; Atwood M; Hanau A; Cohen AT
    Thromb Haemost; 2018 Nov; 118(11):1951-1961. PubMed ID: 30357780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism in lymphoma: how effectively are we treating patients?
    Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Daw HA
    Am J Clin Oncol; 2009 Oct; 32(5):521-3. PubMed ID: 19546801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
    Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
    JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran.
    Harenberg J; Jörg I; Weiss C
    Eur J Clin Pharmacol; 2006 Mar; 62(3):173-7. PubMed ID: 16416154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.